CA2559480A1 - Methods and compositions for inhibition of metastasis - Google Patents

Methods and compositions for inhibition of metastasis Download PDF

Info

Publication number
CA2559480A1
CA2559480A1 CA002559480A CA2559480A CA2559480A1 CA 2559480 A1 CA2559480 A1 CA 2559480A1 CA 002559480 A CA002559480 A CA 002559480A CA 2559480 A CA2559480 A CA 2559480A CA 2559480 A1 CA2559480 A1 CA 2559480A1
Authority
CA
Canada
Prior art keywords
antibody
cell
metastatic
activated
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002559480A
Other languages
English (en)
French (fr)
Inventor
Brunhilde Felding-Habermann
Kim D. Janda
Alan Saven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2559480A1 publication Critical patent/CA2559480A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002559480A 2004-02-13 2005-02-14 Methods and compositions for inhibition of metastasis Abandoned CA2559480A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US54480704P 2004-02-13 2004-02-13
US60/544,807 2004-02-13
US62672604P 2004-11-10 2004-11-10
US60/626,726 2004-11-10
US11/056,825 2005-02-11
US11/056,825 US7271245B2 (en) 2004-02-13 2005-02-11 Methods and compositions for inhibition of metastasis
PCT/US2005/004612 WO2005091805A2 (en) 2004-02-13 2005-02-14 Methods and compositions for inhibition of metastasis

Publications (1)

Publication Number Publication Date
CA2559480A1 true CA2559480A1 (en) 2005-10-06

Family

ID=35056641

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002559480A Abandoned CA2559480A1 (en) 2004-02-13 2005-02-14 Methods and compositions for inhibition of metastasis

Country Status (5)

Country Link
US (2) US7271245B2 (https=)
EP (1) EP1725111A4 (https=)
JP (1) JP2007523650A (https=)
CA (1) CA2559480A1 (https=)
WO (1) WO2005091805A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256299A1 (en) * 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
AU2006270009A1 (en) * 2005-07-18 2007-01-25 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
US20100104572A1 (en) * 2006-11-02 2010-04-29 Sylvie Luria Methods for screening for therapeutic molecules and use of the molecules therefrom
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
WO2009042917A1 (en) * 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
WO2009070753A2 (en) * 2007-11-28 2009-06-04 The Scripps Research Institute Bivalent single chain fv antibody compositions that specifically bind to integrin receptor on a metastatic cell in a mammalian subject
EP2240516B1 (en) * 2007-12-26 2015-07-08 Biotest AG Methods and agents for improving targeting of cd138 expressing tumor cells
WO2009114816A2 (en) * 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Therapeutic cancer antigens
WO2010017083A1 (en) * 2008-08-04 2010-02-11 Wayne State University Methods of treating cancer with cd11b antibodies
US11180812B2 (en) 2012-08-17 2021-11-23 Cornell University Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
SG11201506886TA (en) 2013-03-14 2015-09-29 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
CN105793705A (zh) * 2013-09-30 2016-07-20 X博迪公司 抗原受体的筛选测试
US10844436B2 (en) 2014-04-01 2020-11-24 Cornell University Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
WO2019241847A1 (en) * 2018-06-22 2019-12-26 Baker Heart and Diabetes Institute A therapeutic gpiib/iiia binding-protein drug conjugate and use thereof
WO2020176605A1 (en) * 2019-02-26 2020-09-03 The University Of Vermont And State Agricultural College Antibodies to neoantigens and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
EP0633945B1 (en) 1992-04-03 1998-12-30 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
KR0119887B1 (ko) 1994-06-08 1997-10-30 김광호 반도체 메모리장치의 웨이퍼 번-인 테스트 회로
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
WO1998046265A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Methods for using antagonistic anti-avb3 integrin antibodies
CA2284726A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
AU768329B2 (en) * 1998-12-04 2003-12-11 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor alphavbeta3
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US20020025510A1 (en) 2000-07-26 2002-02-28 Strongin Alex Y. Screening methods based on superactivated alpha V beta 3 integrin
AU2002337954C1 (en) 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
AU2003217930A1 (en) 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents

Also Published As

Publication number Publication date
WO2005091805A3 (en) 2006-09-08
US7271245B2 (en) 2007-09-18
JP2007523650A (ja) 2007-08-23
US20090117096A1 (en) 2009-05-07
US20050255109A1 (en) 2005-11-17
WO2005091805A2 (en) 2005-10-06
EP1725111A2 (en) 2006-11-29
EP1725111A4 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
US20090117096A1 (en) Methods and compositions for inhibition of metastasis
CN104130329B (zh) Trail受体结合剂和其用途
RU2573897C2 (ru) Антитела к cxcr4 и их применение для лечения рака
EP0973550B1 (en) Antagonistic anti-avb3 integrin antibodies
JP2009527500A (ja) 免疫機能を改善するための方法および哺乳動物対象における疾患の防止または処置のための方法
CA2597717A1 (en) Antibodies against cxcr4 and methods of use thereof
US20080267981A1 (en) Compositions and Methods for Delivery of Antitumor Agents
US20230295338A1 (en) A novel antibody binding specifically to human ceacam1/3/5 and use thereof
CA2735433C (en) Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
KR20260040164A (ko) Cd38에 특이적으로 결합하는 항체, 및 이를 위한 제조 방법 및 이의 용도
AU2013201832B2 (en) Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
CN121045380A (zh) Cd19结合分子及其用途

Legal Events

Date Code Title Description
FZDE Discontinued